Weber, Jr.Chie inancial O icer and Treasurer970-498-3112Woodward Go ernor Company1000 East Drake Road ort Collins, Colorado 80525, USATel: 970-482-5811 ax: 970-498-3058Copyright 2009, Market Wire, All rights reser ed.-0-. SBIO and Tragara Announce an Exclusi e Worldwide License Agreement or No elMulti-kinase Inhibitor SB1317SINGAPORE and SAN DIEGO, Jan. 21 /PRNewswire/ SBIO Pte Ltd and TragaraPharmaceuticals Inc. today announced that SBIO has granted a worldwideexclusi e license to Tragara to de elop and commercialize its no elmulti-kinase inhibitor SB1317. Under the terms o the agreement SBIO is eligible to recei e up to US$112.5million in payments. This includes an up ront ee, de elopment and salesmilestone payments and up to double-digit royalties.Additionally, SBIO willper orm certain preclinical acti ities or Tragara under a de ined workplan inreturn or research ees.Tragara is responsible or all IND enabling,de elopment and commercialization acti ities under the agreement.SB1317 is a no el orally-a ailable, multi-kinase inhibitor with excellentpharmacological and pharmaceutical properties. SB1317 de elopment will beinitially ocused on the treatment o hematologic malignancies and Tragarawill also explore the therapeutic potential o the compound's acti ity insolid tumors."Our entire Tragara team is excited about adding SB1317 to our productpipeline," said Thomas M Estok, President and CEO o Tragara.
"SBIOsuccess ully identi ied a promising compound or the treatment o hematological and potentially solid tumors and we look orward to urtherpro iling the compound and mo ing it toward clinical de elopment.""We are pleased to work with Tragara in rapidly ad ancing SB1317 through INDenabling studies to the clinic.We chose Tragara as a partner due to acombination o their experience, exciting clinical de elopment plans andcommitment to speed.Together we will determine the ull breadth o thecompound's competiti e ad antages in a series o preclinical pro iling studiesprior to Tragara ad ancing this product through parallel tracks o clinicalde elopment," said Dr. Jan-Anders Karlsson, CEO o SBIO.About Tragara Pharmaceuticals IncTragara Pharmaceuticals, Inc. is a pri ately-held pharmaceutical company basedin San Diego, Cali .The company is ocused on the clinical and commercialde elopment o proprietary medicines or the treatment o cancer andin lammation. Tragara stri es to pro ide much-needed therapies that willcontribute to patient health through better sur i al and an increase in thequality o li e.Tragara's lead program, Capoxigem(R) (apricoxib, TG01), iscurrently in Phase II clinical de elopment in lung, breast and pancreaticcancers and has completed a Phase II study in in lammation/pain.A secondprogram, an oral multi-kinase inhibitor, TG02 (SB1317), is in late stagepreclinical de elopment.Tragara is managed by a team o entrepreneurs with both Big Pharma and Biotechexperience in the de elopment and commercialization o oncology therapeutics.Its in estors include: Domain Associates, Mitsubishi InternationalCorporation, Morganthaler entures, Ox ord BioScience Partners and ProQuestIn estments. More in ormation about Tragara can be ound at SBIO Pte LtdSBIO is a pri ately-held biotech company ocused on the research and clinicalde elopment o no el targeted small molecule drugs or the treatment o cancerwith leading programs around histone deacetylases (HDAC) and kinases SBIO'slead candidate, SB939, entered the clinic in 2007. SB1518, SBIO's potent andorally-acti e JAK2 inhibitor, also entered the clinic in 2008 and has recei edorphan drug designation rom the U.S DA.
SBIO has entered into ade elopment collaboration, and option & license agreement with OnyxPharmaceuticals, Inc. to de elop and commercialize SB1518 and its other no elJAK2 inhibitor, SB1578.SBIO's SB1317, a no el multi-kinase inhibitor, is inpre-clinical de elopment and under a worldwide exclusi e license with TragaraPharmaceuticals, Inc or its de elopment and commercialization. In line with its ision to be a leading ully-integrated oncology- ocusedbiotech company in Asia Paci ic, SBIO has established a state-o -the-art R&Din rastructure, complemented by a strong clinical de elopment team. SBIO hasstrong links with a network o medical oncologists in Asia Paci ic and itsin estors include BioOne Capital, Ara is entures, No artis Bio entures andother international unds.More in ormation about SBIO can be ound at SBIO Pte Ltd:Russo Partners:Stephen Keith Rhind, Ph.D.Tony Russo 1 212-845-4251Senior ice President,Corporate De elopment Andreas Maratho ouniotisTel: 65 6827 5000 (Singapore)1 Tragara Pharmaceuticals Inc.:Chris LeMastersChie Business O icerTel: 1 858 350 SOURCESBIO Pte LtdStephen Keith Rhind, Ph.D., Senior ice President, Corporate De elopment o SBIO Pte Ltd, 65-6827-5000 (Singapore), ; or TonyRusso, 1-212-845-4251, , or AndreasMaratho ouniotis, 1-212-845-4253, ; orChris LeMasters o Tragara Pharmaceuticals Inc., 1-858-350-6913,. Uni ersity Expands Degree Options with Bachelor o Science in Health SystemsManagementAURORA, Colo.(Business Wire)American Sentinel Uni ersity announced today that it has added a Bachelor o Science degree program in Health Systems Management (HSM) to its alreadyimpressi e array o healthcare degrees.
According to the Bureau o Labor Statistics, 18 o the top 20 astest-growingoccupations between 2004 and 2014 will be in healthcare and computer science.American Sentinel is responding by o ering a new degree program in healthsystems management. "Job opportunities in health systems management are expected to grow by 36percent o er the next 10 years," said Catherine Garner, DrPH, RN, AAN, Dean o Health Pro essions at American Sentinel Uni ersity. Students will acquire abroad knowledge base in computer in ormation systems as they are used inorganizational setting and learn how to apply this knowledge to the speci icneeds o the healthcare in ormation en ironment. "The HSM degree o ers an excellent re-training opportunity or indi iduals witha management or IT background to make the shi t rom other industries such as inance and manu acturing to health care, where there is a projected expansiono employment opportunities," said Dr Garner. In 2005, a national goal was set to create uni ersal electronic medical recordsby 2015. The plan included a detailed strategy to increase the use o in ormation technology (IT) in healthcare and to create national standards thatwould enable medical in ormation to be digitized, stored and sharedelectronically. This initiati e, along with many others, has created a need orquali ied, trained indi iduals to manage complex IT systems in the hospitalen ironment The B.S.